Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $57.50 short put and a strike $52.50 long put offers a potential 5.71% return on risk over the next 23 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $57.50 by expiration. The full premium credit of $0.27 would be kept by the premium seller. The risk of $4.73 would be incurred if the stock dropped below the $52.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Eli Lilly Gains Slightly on Dulaglutide Data
Thu, 27 Feb 2014 20:45:04 GMT
Acadia Pharmaceuticals: Here's What You Should Know About Its Surging Shares
Wed, 26 Feb 2014 19:31:56 GMT
Six New Stocks to Buy in the Piper Jaffray Model Portfolio
Wed, 26 Feb 2014 13:25:56 GMT
LILLY ELI & CO Financials
Tue, 25 Feb 2014 18:04:10 GMT
Lilly weekly diabetes drug as effective as market leader Victoza-study
Tue, 25 Feb 2014 17:28:11 GMT
Reuters – An experimental once-weekly medicine for type 2 diabetes developed by Eli Lilly and Co proved as effective in lowering blood sugar as Victoza from Danish drugmaker Novo Nordisk in an eagerly anticipated late stage study. The Lilly drug, dulaglutide, achieved the primary goal of the 599-patient study by demonstrating so-called non-inferiority to the highest approved dose of Victoza after 26 weeks, according to initial results released by the company on Tuesday. Dulaglutide, considered one of the more important medicines in Lilly's pipeline of drugs in development, is awaiting U.S. and European approval decisions. “It is our hope that we will have approval this year,” Lilly's Senior Medical Director Sherry Martin said in a telephone interview.
Also on Market Tamer…
Follow Us on Facebook